Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev.
Mallinckrodt acquired Ofirmev in 2014, when it bought Cadence Pharmaceuticals in a $1.4 billion deal. In May of that year, Mallinckrodt hiked the pain-killer’s list price from $14.75 per vial to $35.40 per vial.
Get the full story at our sister site, Drug Delivery Business News.
The post Mallinckrodt faces probe over price hikes for injectable pain-killer appeared first on MassDevice.
from MassDevice http://ift.tt/2qy5ILJ
Cap comentari:
Publica un comentari a l'entrada